journal of controlled release Journal of Controlled Release 53 (1998) 311-313 Author Index Volume 53 (1998) Ahn, B.-Y., see Cho, N.-H. (53) 215 Dankert, J., see Kuijpers, A.J. (53) 235 Akaike, T., see Kim, J.-S. (53) 175 Dedrick, R.L., see Flessner, M.F. (53) 69 Andersen, C., see Br@ndsted, H. (53) 7 DeSilva, B.S., see Topp, E.M. (53) 15 Aoyagi, T., see Chung, J.E. (53) 119 Dumoulin, Y., see Lenaerts, V. (53) 225 August, J.T., see Leong, K.W. (53) 183 Aukerman, L., see Cappello, J. (53) 105 Engbers, G.H.M., see Kuijpers, A.J. (53) 235 Aynie, I., see Fattal, E. (53) 137 Engel, R., see Vert, M. (53) 85 Bae, Y.H., Vernon, B., Han, C.K. and Kim, S.W., Extracellular Farr, S.J., see Gonda, I. (53) 269 matrix for a rechargeable cell delivery system (53) 249 Fattal, E., Vauthier, C., Aynie, I., Nakada, Y., Lambert, G., Malvy, Barenholz, Y., see Gabizon, A. (53) 275 C. and Couvreur, P., Biodegradable polyalkylcyanoacrylate Brgndsted, H., Andersen, C. and Hovgaard, L., Crosslinked nanoparticles for the delivery of oligonucleotides (53) 137 dextran — a new capsule material for colon targeting of drugs Feijen, J., see Kuijpers, A.J. (53) 235 (53) 7 Ferrari, F.A., see Cappello, J. (53) 105 Brown, J.E., see Markou, C.P. (53) 281 Flessner, M.F. and Dedrick, R.L., Tissue-level transport mecha- Burman, D., see Cappello, J. (53) 105 nisms of intraperitoneally-administered monoclonal antibodies (53) 69 Cappello, J., Crissman, J.W., Crissman, M., Ferrari, F.A., Textor, Freire, E., see Milstein, S.J. (53) 259 G., Wallis, O., Whitledge, J.R., Zhou, X., Burman, D., Au- kerman, L. and Stedronsky, E.R., In-situ self-assembling Gabizon, A., Goren, D., Cohen, R. and Barenholz, Y., Develop- protein polymer gel systems for administration, delivery, and ment of liposomal anthracyclines: from basics to clinical release of drugs (53) 105 applications (53) 275 Cartilier, L., see Lenaerts,V . (53) 225 Gentry, C., see Omelyanenko, V. (53) 25 Chan Kwon, I., see Cho, N.-H. (53) 215 Gonda, I., Schuster, J.A., Rubsamen, R.M., Lloyd, P., Cipolla, D. Cherng, J.-Y., see van de Wetering, P. (53) 145 and Farr, S.J., Inhalation delivery systems with compliance Cho, B.K., see Kranz, D.M. (53) 77 and disease management capabilities (53) 269 Cho, N.-H., Seong, S.-Y., Chun, K.-H., Kim, Y.-H., Chan Kwon, Goren, D., see Gabizon, A. (53) 275 I., Ahn, B.-Y. and Jeong, S.Y., Novel mucosal immunization Gruber, M.M., see Kranz, D.M. (53) 77 with polysaccharide—protein conjugates entrapped in alginate microspheres (53) 215 Haller, M.F. and Saltzman, W.M., Nerve growth factor delivery Chouinard, F., see Lenaerts, V. (53) 225 systems (53) 1 Chun, K.-H., see Cho, N.-H. (53) 215 Han, C.K., see Bae, Y.H. (53) 249 Chung, J.E., Yokoyama, M., Aoyagi, T., Sakurai, Y. and Okano, Hanson, S.R., see Markou, C.P. (53) 281 T., Effect of molecular architecture of hydrophobically modi- Hashida, M., Takemura, S., Nishikawa, M. and Takakura, Y., fied poly(N-isopropylacrylamide) on the formation of ther- Targeted delivery of plasmid DNA complexed with galac- moresponsive core-shell micellar drug carriers (53) 119 tosylated poly(L-lysine) (53) 301 Cipolla, D., see Gonda, I. (53) 269 Hendrickson, T.L., see Topp, E.M. (53) 15 Cohen, R., see Gabizon, A. (53) 275 Hennink, W.E., see van de Wetering, P. (53) 145 Coudane, J., see Vert, M. (53) 85 Hovgaard, L., see Brgndsted, H. (53) 7 Couvreur, P., see Fattal, E. (53) 137 Crissman, J.W., see Cappello, J. (53) 105 Jain, R.K., Delivery of molecular and cellular medicine to solid Crissman, M., see Cappello, J. (53) 105 tumors (53) 49 Crommelin, D.J.A., see van de Wetering, P. (53) 145 Jeong, S.Y., see Cho, N.-H. (53) 215 PIT §0168-3659(98)00048-0 312 Author Index Volume 53 (1998) Kasimova, M., see Milstein, S.J. (53) 259 unfolded proteins efficiently penetrate cell membranes — Kataoka, K., see Yu, B.G. (53) 131 implications for oral drug delivery (53) 259 Kim, B.-I., see Kim, J.-S. (53) 175 Mlynek, G.M., see Milstein, S.J. (53) 259 Kim, J.-S., Kim, B.-I., Maruyama, A., Akaike, T. and Kim, S.W., Moss, S.H., see Pouton, C.W. (53) 289 A new non-viral DNA delivery vector: the terplex system (53) Moussa, I., see Lenaerts, V. (53) 225 175 Kim, S.W., see Kim, J.-S. (53) 175 Nakada, Y., see Fattal, E. (53) 137 Kim, S.W., see Bae, Y.H. (53) 249 Nishikawa, M., see Hashida, M. (53) 301 Kim, Y.-H., see Cho, N.-H. (53) 215 Nugent, M.A., see Trinkaus-Randall, V. (53) 205 Kissel, T. and Werner, U., Nasal delivery of peptides: an in vitro cell culture model for the investigation of transport and Ohkawa, J., see Koseki, S. (53) 159 metabolism in human nasal epithelium (53) 195 Okano, T., see Chung, J.E. (53) 119 Kitos, P.A., see Topp, E.M. (53) 15 Okano, T., see Yu, B.G. (53) 131 Kopeéek, J., see Omelyanenko, V. (53) 25 Omelyanenko, V., Kopeckova, P., Gentry, C. and Kopecek, J., Kopeckova, P., see Omelyanenko, V. (53) 25 Targetable HPMA copolymer-adriamycin conjugates. Recog- Koseki, S., Ohkawa, J., Yamamoto, R., Takebe, Y. and Taira, K., A simple assay system for examination of the inhibitory nition, internalization, and subcellular fate (53) 25 potential in vivo of decoy RNAs, ribozymes and other drugs Pouton, C.W., Lucas, P., Thomas, B.J., Uduehi, A.N., Milroy, D.A. by measuring the Tat-mediated transcription of a fusion gene composed of the long terminal repeat of HIV-1 and a gene for and Moss, S.H., Polycation-DNA complexes for gene delivery: a comparison of the biopharmaceutical properties of cationic luciferase (53) 159 Kranz, D.M., Manning, T.C., Rund, L.A., Cho, B.K., Gruber, polypeptides and cationic lipids (53) 289 M.M. and Roy, E.J., Targeting tumor cells with bispecific Prestwich, G.D., Marecak, D.M., Marecek, J.F., Vercruysse, K.P. antibodies and T cells (53) 77 and Ziebell, M.R., Controlled chemical modification of hy- Krijgsveld, J., see Kuijpers, A.J. (53) 235 aluronic acid: synthesis, applications, and biodegradation of Kuijpers, A.J., Engbers, G.H.M., van Wachem, P.B., Krijgsveld, J., hydrazide derivatives (53) 93 Zaat, S.A.J., Dankert, J. and Feijen, J., Controlled delivery of Pursley, M.D., see Markou, C.P. (53) 281 antibacterial proteins from biodegradable matrices (53) 235 Kwon, G., see Yu, B.G. (53) 131 Robinson, J.R., see Milstein, S.J. (53) 259 Roy, E.J., see Kranz, D.M. (53) 77 Lambert, G., see Fattal, E. (53) 137 Roy, K., see Leong, K.W. (53) 183 Leipold, H., see Milstein, S.J. (53) 259 Rubsamen, R.M., see Gonda, I. (53) 269 Lenaerts,V .,M oussa, I., Dumoulin, Y., Mebsout, F., Chouinard, F., Rund, L.A., see Kranz, D.M. (53) 77 Szabo, P., Mateescu, M.A., Cartilier, L. and Marchessault, R.., Cross-linked high amylose starch for controlled release of Sakurai, Y., see Chung, J.E. (53) 119 drugs: recent advances (53) 225 Saltzman, W.M., see Haller, M.F. (53) 1 Leone-Bay, A., see Milstein, S.J. (53) 259 Sarubbi, D., see Milstein, S.J. (53) 259 Leong, K.W., Mao, H.-Q., Truong-Le, V.L., Roy, K., Walsh, S.M. Schuster, J.A., see Gonda, I. (53) 269 and August, J.T., DNA-polycation nanospheres as non-viral Schwach, G., see Vert, M. (53) 85 gene delivery vehicles (53) 183 Seong, S.-Y., see Cho, N.-H. (53) 215 Lloyd, P., see Gonda, I. (53) 269 Stedronsky, E.R., see Cappello, J. (53) 105 Low, P.S., see Wang, S. (53) 39 Szabo, P., see Lenaerts,V . (53) 225 Lucas, P., see Pouton, C.W. (53) 289 Taira, K., see Koseki, S. (53) 159 Malvy, C., see Fattal, E. (53) 137 Takakura, Y., see Hashida, M. (53) 301 Manning, T.C., see Kranz, D.M. (53) 77 Takebe, Y., see Koseki, S. (53) 159 Mao, H.-Q., see Leong, K.W. (53) 183 Takemura, S., see Hashida, M. (53) 301 Marchessault, R., see Lenaerts, V. (53) 225 Talsma, H., see van de Wetering, P. (53) 145 Marecak, D.M., see Prestwich, G.D. (53) 93 Textor, G., see Cappello, J. (53) 105 Marecek, J.F., see Prestwich, G.D. (53) 93 Thomas, B.J., see Pouton, C.W. (53) 289 Markou, C.P., Brown, J.E., Pursley, M.D. and Hanson, S.R., Topp, E.M., Kitos, P.A., Vijaykumar, V., DeSilva, B.S. and Boundary layer drug delivery using a helical catheter (53) 281 Hendrickson, T.L., Antibody transport in cultured tumor cell Maruyama, A., see Kim, J.-S. (53) 175 layers (53) 15 Mateescu, M.A., see Lenaerts, V. (53) 225 Trinkaus-Randall, V. and Nugent, M.A., Biological response to a Mebsout, F., see Lenaerts, V. (53) 225 synthetic cornea (53) 205 Milroy, D.A., see Pouton, C.W. (53) 289 Truong-Le, V.L., see Leong, K.W. (53) 183 Milstein, S.J., Leipold, H., Sarubbi, D., Leone-Bay, A., Mlynek, G.M., Robinson, J.R., Kasimova, M. and Freire, E., Partially Uduehi, A.N., see Pouton, C.W. (53) 289 Author Index Volume 53 (1998) 313 van de Wetering, P., Cherng, J.-Y., Talsma, H., Crommelin, D.J.A. tic drugs, imaging agents, and nucleic acids to cancer cells and Hennink, W.E., 2-(dimethylamino)ethyl methacrylate (53) 39 based (co)polymers as gene transfer agents (53) 145 Werner, U., see Kissel, T. (53) 195 van Wachem, P.B., see Kuijpers, A.J. (53) 235 Whitledge, J.R., see Cappello, J. (53) 105 Vauthier, C., see Fattal, E. (53) 137 Vercruysse, K.P., see Prestwich, G.D. (53) 93 Yamamoto, R., see Koseki, S. (53) 159 Vernon, B., see Bae, Y.H. (53) 249 Yokoyama, M., see Chung, J.E. (53) 119 Vert, M., Schwach, G., Engel, R. and Coudane, J., Something new Yu, B.G., Okano, T., Kataoka, K. and Kwon, G., Polymeric in the field of PLA/GA bioresorbable polymers? (53) 85 micelles for drug delivery: solubilization and haemolytic Vijaykumar,V. , see Topp, E.M. (53) 15 activity of amphotericin B (53) 131 Wagner, E., Effects of membrane-active agents in gene delivery Zaat, S.A.J., see Kuijpers, A.J. (53) 235 (53) 155 Zhou, X., see Cappello, J. (53) 105 Wallis, O., see Cappello, J. (53) 105 Ziebell, M.R., see Prestwich, G.D. (53) 93 Walsh, S.M., see Leong, K.W. (53) 183 Wang, S. and Low, P.S., Folate-mediated targeting of antineoplas- journal of controlled release Journal of Controlled Release 53 (1998) 315-316 Subject Index Volume 53 (1998) Adsorption, (53) 137 Dextran, (53) 7 Aerosols, (53) 269 Differentiated epithelia, (53) 289 Alginate, (53) 205 Diffusion and convection, (53) 49 Alginate microsphere, (53) 215 Diffusion, (53) 15, (53) 69 Alzheimer’s disease, (53) 1 Disease management, (53) 269 Amphipathic peptides, (53) 155 Drug release, (53) 7, (53) 25 Amphotericin B, (53) 131 Endocarditis, (53) 235 Angiogenesis, (53) 49 Endosome destabilization, (53) 155 Antibacterial proteins, (53) 235 Epidermal growth factor, (53) 1 Antibody binding, (53) 69 Folate receptor, (53) 77 Antisense oligonucleotide, (53) 175 Folate receptor-mediated endocytosis, (53) 39 Biocompatible hydrogel, (53) 93 AG (change in Gibbs free energy), (53) 259 Biodegradation, (53) 7 B-galactosidase, (53) 145 Biohybrid artificial pancreas, (53) 249 Galactosylated poly(1-lysine), (53) 301 Biomaterial, (53) 93 Gelatin, (53) 235 Bioresorbable polymers, (53) 85 Gene delivery, (53) 183, (53) 289 Bispecific antibodies, (53) 77 Gene therapy, (53) 289, (53) 301 Blood flow, (53) 49 Gene transfer, (53) 183 Cancer cell targeting, (53) 39 Growth factors, (53) 1, (53) 205 Cancer chemotherapy, (53) 39 HIV-1, (53) 159 Cancer detection and treatment, (53) 49 HPMA copolymer, (53) 25 Capsule, (53) 7 Haemolysis, (53) 131 Carbodiimide, (53) 235 Hepatic uptake, (53) 301 Cationic carriers, (53) 145 Human nasal epithelial cells, (53) 195 Cationic lipids, (53) 289 Hyaluronidase, (53) 93 Cell adhesion and deformation, (53) 49 Hydrocortisone, (53) 93 Cell culture model, (53) 195 Hydrolysis, (53) 85 Cell transplantation, (53) 1 Hydrophilic matrices, (53) 225 Colon-specific drug delivery, (53) 7 Hysteresis, (53) 249 Compliance, (53) 269 Immunoconjugates, (53) 15 Confocal microscopy, (53) 25 Immunoglobulin, (53) 69 Controlled release, (53) 1, (53) 205, (53) 225 Inhalation, (53) 269 Convection, (53) 15, (53) 69 Inhibition, (53) 159 Cross-linked starch, (53) 225 Initiator, (53) 85 Cross-linking, (53) 235 Intermediate conformation, (53) 259 Cytosolic delivery, (53) 155 Interstitial pressure, (53) 49 Cytotoxic T lymphocytes, (53) 77 Intracellular delivery, (53) 137 DNA condensation, (53) 289 Islets, (53) 249 DNA nanoparticles, (53) 183 Local drug delivery, (53) 281 DNA transfection, (53) 155 Luciferase, (53) 159 DNA, (53) 145 Lymphatics, (53) 49 Decoy, (53) 159 Microprocessors, (53) 269 Degradation mechanism, (53) 85 Model tumor, (53) 15 PIT $0168-3659(98)00049-2 316 Subject Index Volume 53 (1998) Molten globule state, (53) 259 Protein polymer, (53) 105 Morphogen, (53) 1 Receptor—ligand binding, (53) 49 } Mucosal immunization, (53) 215 Receptor-mediated gene delivery, (53) 155 N-Isopropylacrylamide copolymers, (53) 249 Ribozyme, (53) 159 F Nanospheres, (53) 183 Sequential block copolymers, (53) 105 4 Nasal metabolism, (53) 195 Silk—elastinlike protein combinations, (53) 105 : Nasal transport, (53) 195 Size distribution, (53) 131 i Nerve growth factor, (53) 1 Subcellular trafficking, (53) 25 ; Non-viral, (53) 183 Synthetic cornea, (53) 205 Oral vaccine, (53) 215 T,, (melting temperature), (53) 259 PEO-PBLA micelles, (53) 131 TEM, (53) 131 Passive diffusion, (53) 259 Targeted imaging agents, (53) 39 Peptides, (53) 195 Terminal modification, (53) 119 Pharmacokinetics, (53) 301 Terplex system, (53) 175 Phase transition, (53) 119 Thermoresponse, (53) 119 4 Plasmid DNA, (53) 301 Thermoreversible gelation, (53) 249 4 Pneumococcal pneumonia, (53) 215 Thrombosis, (53) 281 Poly(2-(dimethylamino)ethyl methacrylate), (53) 145 Tissue distribution, (53) 137 Poly(N-isopropylacrylamide), (53) 119 Transfection, (53) 145, (53) 175, (53) 289 Polyalkylcyanoacrylate nanoparticles, (53) 137 Transgenic mice, (53) 77 Polycations, (53) 289 Tumor microcirculation, (53) 49 Polyfunctional crosslinker, (53) 93 Tumor penetration, (53) 15 Polylactides, (53) 85 Vascular permeability, (53) 49 Polylysine, (53) 289 Wound repair, (53) 205 Polymeric micelle, (53) 119 Zero-order release, (53) 225 Polymer, (53) 1